A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes

References

• AljabriKKozakSEThompsonDMAddition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trialAm J Med2004116230514969650
   PubMed Web of Science ®Google Scholar
• AronoffSRosenblattSBraithwaiteSPioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupDiabetes Care20002316051111092281
   PubMed Web of Science ®Google Scholar
• AshcroftFMRorsmanPElectrophysiology of the pancreatic beta-cellProg Biophys Mol Biol198954871432484976
   PubMed Web of Science ®Google Scholar
• BalfourJAPloskerGLRosiglitazoneDrugs19995792130 discussion 931–210400405
   PubMed Web of Science ®Google Scholar
• BelcherGLambertCEdwardsGSafety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetesDiabetes Res Clin Pract200570536216002175
   PubMed Web of Science ®Google Scholar
• BelfortRHarrisonSABrownKA placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitisN Engl J Med2006355229730717135584
   PubMed Web of Science ®Google Scholar
• BerhanuPKipnesMSKhanMAEffects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapyDiab Vasc Dis Res20063394416784180
   PubMedGoogle Scholar
• BetteridgeDJVergesBLong-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetesDiabetologia20054824778116283239
   PubMed Web of Science ®Google Scholar
• BijlstraPJLuttermanJARusselFGInteraction of sulphonylurea derivatives with vascular ATP-sensitive potassium channels in humansDiabetologia1996391083908877293
   PubMed Web of Science ®Google Scholar
• BoylePJKingABOlanskyLEffects of pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: a retrospective review of randomly selected medical recordsClin Ther2002243789611952022
   PubMed Web of Science ®Google Scholar
• CaldwellSHHespenheideEERedickJAA pilot study of a thiazolidinedione, troglitazone,in nonalcoholic steatohepatitisAm J Gastroenterol2001965192511232700
   PubMed Web of Science ®Google Scholar
• CampbellRKGlimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitusAnn Pharmacother1998321044529793597
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetologia200548109310415889234
   PubMed Web of Science ®Google Scholar
• DahlemYAHornTFBuntinasLThe human mitochondrial KATP channel is modulated by calcium and nitric oxide: a patch-clamp approachBiochim Biophys Acta20041656465615136158
   PubMed Web of Science ®Google Scholar
• DanchinNCharpentierGLedruFRole of previous treatment with sulfonylureas in diabetic patients with acute myocardial infarction: results from a nationwide French registryDiabetes Metab Res Rev200521143915386810
   PubMed Web of Science ®Google Scholar
• DavidsonJAPerezAZhangJAddition of pioglitazone to stable insulin therapy in patients with poorly controlled type 2 diabetes: results of a double-blind, multicentre, randomized studyDiabetes Obes Metab200681647416448520
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFD’AngeloAEffects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein a. and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trialClin Ther2006286798816861090
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFDangeloAThiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepirideHypertens Res2005a289172416555581
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract2005b6951315955382
   PubMed Web of Science ®Google Scholar
• DillsDGSchneiderJClinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Glimepiride/Glyburide Research GroupHorm Metab Res19962842698911977
   PubMed Web of Science ®Google Scholar
• DorkhanMMagnussonMFridAGlycaemic and nonglycaemic effects of pioglitazone in triple oral therapy of patients with type 2 diabetesJ Intern Med20062601253316882276
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study PROspective pioglitAzone Clinical Trial In macroVascular Events: a randomised controlled trialLancet200536612798916214598
   PubMed Web of Science ®Google Scholar
• DraegerKEWernicke-PantenKLompHJLong-term treatment of type 2 diabetic patients with the new oral antidiabetic agent glimepiride Amaryl: a double-blind comparison with glibenclamideHorm Metab Res199628419258911976
   PubMed Web of Science ®Google Scholar
• DuboisMPattouFKerr-ConteJExpression of peroxisome proliferator-activated receptor gamma PPARgamma. in normal human pancreatic islet cellsDiabetologia2000431165911043863
   PubMed Web of Science ®Google Scholar
• DuezHChaoYSHernandezMReduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in miceJ Biol Chem200227748051712377786
   PubMed Web of Science ®Google Scholar
• EinhornDRendellMRosenzweigJPioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupClin Ther200022139540911192132
   PubMed Web of Science ®Google Scholar
• EliassonLRenstromEAmmalaCPKC-dependent stimulation of exocytosis by sulfonylureas in pancreatic beta cellsScience199627181358628999
   PubMed Web of Science ®Google Scholar
• FeinglosMNBethelMATreatment of type 2 diabetes mellitusMed Clin North Am199882757909706120
   PubMed Web of Science ®Google Scholar
• FormanBMTontonozPChenJ15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gammaCell199583803128521497
   PubMed Web of Science ®Google Scholar
• ForstTHohbergCFuellertSDPharmacological PPARgamma stimulation in contrast to beta cell stimulation results in an improvement in adiponectin and proinsulin intact levels and reduces intima media thickness in patients with type 2 diabetesHorm Metab Res2005a37521716138267
   PubMed Web of Science ®Google Scholar
• ForstTLubbenGHohbergCInfluence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2Microcirculation2005b125435016207627
   PubMed Web of Science ®Google Scholar
• FukuenSIwakiMYasuiASulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activityJ Biol Chem200528023653915764598
   PubMed Web of Science ®Google Scholar
• FullertSSchneiderFHaakEEffects of pioglitazone in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled studyJ Clin Endocrinol Metab2002875503612466345
   PubMed Web of Science ®Google Scholar
• GeisenKVeghAKrauseECardiovascular effects of conventional sulfonylureas and glimepirideHorm Metab Res1996284965078911987
   PubMed Web of Science ®Google Scholar
• GerberPLubbenGHeuslerSEffects of pioglitazone on metabolic control and blood pressure: a randomised study in patients with type 2 diabetes mellitusCurr Med Res Opin200319532914594526
   PubMed Web of Science ®Google Scholar
• GersteinHCYusufSBoschJEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet2006368109610516997664
   PubMed Web of Science ®Google Scholar
• GhoshSStandenNBGalinianesMFailure to precondition pathological human myocardiumJ Am Coll Cardiol200137711811693741
   PubMed Web of Science ®Google Scholar
• GilliesPSDunnCJPioglitazoneDrugs20006033343 discussion 344–510983737
   PubMed Web of Science ®Google Scholar
• GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care20052815475415983299
   PubMed Web of Science ®Google Scholar
• GossetPCharbonnierASDelerivePPeroxisome proliferator-activated receptor gamma activators affect the maturation of human monocyte-derived dendritic cellsEur J Immunol20013128576511592060
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care200427141714693980
   PubMed Web of Science ®Google Scholar
• HellmanBSehlinJTaljedalIBGlibenclamide is exceptional among hypoglycaemic sulphonylureas in accumulating progressively in beta-cell-rich pancreatic isletsActa Endocrinol Copenh1984105385906230850
   PubMedGoogle Scholar
• HenryRRThiazolidinedionesEndocrinol Metab Clin North Am199726553739314015
   PubMed Web of Science ®Google Scholar
• HerzMJohnsDReviriegoJA randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitusClin Ther20032510749512809958
   PubMed Web of Science ®Google Scholar
• InukaiKWatanabeMNakashimaYGlimepiride enhances intrinsic peroxisome proliferator-activated receptor-gamma activity in 3T3-L1 adipocytesBiochem Biophys Res Commun20053284849015694373
   PubMed Web of Science ®Google Scholar
• InzucchiSEOral antihyperglycemic therapy for type 2 diabetes: scientific reviewJAMA20022873607211790216
   PubMed Web of Science ®Google Scholar
• IRISThe IRIS III study: pioglitazone improves metabolic control and blood pressure in patients with type 2 diabetes without increasing body weightDiabetes, Obesity and Metabolism200791323
   PubMed Web of Science ®Google Scholar
• JainROseiKKupferSLong-term safety of pioglitazone versus glyburide in patients with recently diagnosed type 2 diabetes mellitusPharmacotherapy20062613889516999648
   PubMed Web of Science ®Google Scholar
• JernbergTJamesSLindahlBNatriuretic peptides in unstable coronary artery diseaseEur Heart J20042514869315342167
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAGlycemic durability of rosiglitazone, metformin, or glyburide monotherapyN Engl J Med200635524274317145742
   PubMed Web of Science ®Google Scholar
• KanataniYUsuiIIshizukaKEffects of pioglitazone on suppressor of cytokine signaling 3 expression: potential mechanisms for its effects on insulin sensitivity and adiponectin expressionDiabetes20075679580317327450
   PubMed Web of Science ®Google Scholar
• KaramJHMatinSBForshamPHAntidiabetic drugs after the University Group Diabetes Program UGDPAnnu Rev Pharmacol197515351661096790
   PubMedGoogle Scholar
• KarthikeyanVJLipGYN-terminal pro-brain natriuretic peptide and coronary artery diseaseEur J Clin Invest2007371717181561
   PubMed Web of Science ®Google Scholar
• KawamoriRMatsuhisaMKinoshitaJPioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study GroupDiabetes Res Clin Pract19984135439768370
   PubMed Web of Science ®Google Scholar
• KhanMXuYEdwardsGEffects of pioglitazone on the components of diabetic dyslipidaemia: results of double-blind, multicentre, randomised studiesInt J Clin Pract2004589071215587767
   PubMed Web of Science ®Google Scholar
• KipnesMSKrosnickARendellMSPioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled studyAm J Med200111110711448655
   PubMed Web of Science ®Google Scholar
• KlepzigHKoberGMatterCSulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamideEur Heart J1999204394610213347
   PubMed Web of Science ®Google Scholar
• KramerWMullerGGirbigFDifferential interaction of glimepiride and glibenclamide with the beta-cell sulfonylurea receptor. II. Photoaffinity labeling of a 65 kDa protein by [3H]glimepirideBiochim Biophys Acta19941191278908172913
   PubMed Web of Science ®Google Scholar
• LangenfeldMRForstTHohbergCPioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized studyCirculation200511125253115883215
   PubMed Web of Science ®Google Scholar
• LeeTMChouTFImpairment of myocardial protection in type 2 diabetic patientsJ Clin Endocrinol Metab200388531712574175
   PubMed Web of Science ®Google Scholar
• LehmannJMMooreLBSmith-OliverTAAn antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma PPAR gammaJ Biol Chem19952701295367768881
   PubMed Web of Science ®Google Scholar
• LehtihetMWelshNBerggrenPOGlibenclamide inhibits islet carnitine palmitoyltransferase 1 activity, leading to PKC-dependent insulin exocytosisAm J Physiol Endocrinol Metab2003285E4384612684219
   PubMed Web of Science ®Google Scholar
• LembergerTDesvergneBWahliWPeroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiologyAnnu Rev Cell Dev Biol199612335638970730
   PubMed Web of Science ®Google Scholar
• Luis BautistaJBugosCDirnbergerGEfficacy and safety profile of glimepiride in Mexican American patients with type 2 diabetes mellitus: a randomized, placebo-controlled studyClin Ther20032519420912637120
   PubMed Web of Science ®Google Scholar
• MartensFMRabelinkTJop’t RoodtJTNF-alpha induces endothelial dysfunction in diabetic adults, an effect reversible by the PPAR-gamma agonist pioglitazoneEur Heart J2006271605916762982
   PubMed Web of Science ®Google Scholar
• MartensFMVisserenFLde KoningEJShort-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetesJ Cardiovasc Pharmacol200546773816306801
   PubMed Web of Science ®Google Scholar
• MarxNMachFSautyAPeroxisome proliferator-activated receptor-gamma activators inhibit IFN-gamma-induced expression of the T cell-active CXC chemokines IP-10, Mig, and I-TAC in human endothelial cellsJ Immunol20001646503810843708
   PubMed Web of Science ®Google Scholar
• MarxNWohrleJNusserTPioglitazone reduces neointima volume after coronary stent implantation: a randomized, placebo-controlled, double-blind trial in nondiabetic patientsCirculation20051122792816246947
   PubMed Web of Science ®Google Scholar
• MattooVEcklandDWidelMMetabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group studyClin Ther2005275546715978304
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialJAMA200629625728117101640
   PubMed Web of Science ®Google Scholar
• MiyazakiYGlassLTriplittCEffect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patientsDiabetologia2001a442210911793023
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMImproved glycemic control and enhanced insulin sensitivity in type 2 diabetic subjects treated with pioglitazoneDiabetes Care2001b24710911315836
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAMatsudaMEffect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab2002a8727849112050251
   PubMed Web of Science ®Google Scholar
• MiyazakiYMahankaliAWajcbergEEffect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patientsJ Clin Endocrinol Metab2004894312915356026
   PubMed Web of Science ®Google Scholar
• MiyazakiYMatsudaMDeFronzoRADose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetesDiabetes Care2002b255172311874940
   PubMed Web of Science ®Google Scholar
• MocanuMMMaddockHLBaxterGFGlimepiride, a novel sulfonylurea, does not abolish myocardial protection afforded by either ischemic preconditioning or diazoxideCirculation20011033111611425777
   PubMed Web of Science ®Google Scholar
• NakamuraTMatsudaTKawagoeYEffect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patientsMetabolism2004531382615375799
   PubMed Web of Science ®Google Scholar
• Neuschwander-TetriBABruntEMWehmeierKRImproved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazoneHepatology20033810081714512888
   PubMed Web of Science ®Google Scholar
• NicholsCGLedererWJAdenosine triphosphate-sensitive potassium channels in the cardiovascular systemAm J Physiol1991261H1675861750525
   PubMed Web of Science ®Google Scholar
• NishioKSakuraiMKusuyamaTA randomized comparison of pioglitazone to inhibit restenosis after coronary stenting in patients with type 2 diabetesDiabetes Care200629101616373904
   PubMed Web of Science ®Google Scholar
• NolanJJLudvikBBeerdsenPImprovement in glucose tolerance and insulin resistance in obese subjects treated with troglitazoneN Engl J Med19943311188937935656
   PubMed Web of Science ®Google Scholar
• PanzramGMortality and survival in type 2 non-insulin-dependent. diabetes mellitusDiabetologia198730123313556287
   PubMed Web of Science ®Google Scholar
• PavoIJermendyGVarkonyiTTEffect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesJ Clin Endocrinol Metab20038816374512679450
   PubMed Web of Science ®Google Scholar
• PerezAKhanMJohnsonTPioglitazone plus a sulphonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetesDiab Vasc Dis Res20041445016305056
   PubMedGoogle Scholar
• PfutznerAHohbergCLubbenGPioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose controlHorm Metab Res2005a37510516138265
   PubMed Web of Science ®Google Scholar
• PfutznerAMarxNLubbenGImprovement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the pioneer studyJ Am Coll Cardiol2005b4519253115963388
   PubMed Web of Science ®Google Scholar
• PhatakHMYinDDFactors associated with the effect-size of thiazolidinedione TZD. therapy on HbA1c: a meta-analysis of published randomized clinical trialsCurr Med Res Opin20062222677817076987
   PubMed Web of Science ®Google Scholar
• ProksPReimannFGreenNSulfonylurea stimulation of insulin secretionDiabetes200251Suppl 3S3687612475777
   PubMed Web of Science ®Google Scholar
• ProutTEA prospective view of the treatment of adult-onset diabetes with special reference to the University Group Diabetes Program and oral hypoglycemic agentsMed Clin North Am1971551065754946757
   PubMed Web of Science ®Google Scholar
• QuastUStephanDBiegerSThe impact of ATP-sensitive K+ channel subtype selectivity of insulin secretagogues for the coronary vasculature and the myocardiumDiabetes200453Suppl 3S1566415561904
   PubMed Web of Science ®Google Scholar
• QuayleJMNelsonMTStandenNBATP-sensitive and inwardly rectifying potassium channels in smooth musclePhysiol Rev19977711652329354814
   PubMed Web of Science ®Google Scholar
• RasouliNRaueUMilesLMPioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissueAm J Physiol Endocrinol Metab2005288E930415632102
   PubMed Web of Science ®Google Scholar
• RichterBBandeira-EchtlerEBergerhoffKPioglitazone for type 2 diabetes mellitusCochrane Database Syst Rev2006CD00606017054272
   PubMed Web of Science ®Google Scholar
• RivelineJPDanchinNLedruFSulfonylureas and cardiovascular effects: from experimental data to clinical use. Available data in humans and clinical applicationsDiabetes Metab2003292072212909809
   PubMed Web of Science ®Google Scholar
• RosenblattSMiskinBGlazerNBThe impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitusCoron Artery Dis2001124132311491207
   PubMed Web of Science ®Google Scholar
• RosenstockJEinhornDHershonKEfficacy and safety of pioglitazone in type 2 diabetes: a randomized, placebo-controlled study in patients receiving stable insulin therapyInt J Clin Pract200256251712074206
   PubMed Web of Science ®Google Scholar
• RosenstockJSamolsEMuchmoreDBGlimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study GroupDiabetes Care199619119498908379
   PubMed Web of Science ®Google Scholar
• RubinsHBRobinsSJCollinsDGemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study GroupN Engl J Med1999341410810438259
   PubMed Web of Science ®Google Scholar
• SaltielAROlefskyJMThiazolidinediones in the treatment of insulin resistance and type II diabetesDiabetes199645166198922349
   PubMed Web of Science ®Google Scholar
• SanyalAJMofradPSContosMJA pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitisClin Gastroenterol Hepatol2004211071515625656
   PubMed Web of Science ®Google Scholar
• SarafidisPABakrisGLProtection of the kidney by thiazolidinediones: an assessment from bench to bedsideKidney Int20067012233316883325
   PubMed Web of Science ®Google Scholar
• SatoTNishidaHMiyazakiMNakayaHEffects of sulfonylureas on mitochondrial ATP-sensitive K+ channels in cardiac myocytes: implications for sulfonylurea controversyDiabetes Metab Res Rev200622341716444778
   PubMed Web of Science ®Google Scholar
• ScherbaumWAGokeBMetabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled studyHorm Metab Res2002345899512439788
   PubMed Web of Science ®Google Scholar
• SchernthanerGGrimaldiADi MarioUGUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patientsEur J Clin Invest2004a345354215305887
   PubMed Web of Science ®Google Scholar
• SchernthanerGMatthewsDRCharbonnelBEfficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trialJ Clin Endocrinol Metab2004b8960687615579760
   PubMed Web of Science ®Google Scholar
• SchwartzAVSellmeyerDEVittinghoffEThiazolidinedione use and bone loss in older diabetic adultsJ Clin Endocrinol Metab20069133495416608888
   PubMed Web of Science ®Google Scholar
• ShadidSJensenMDEffects of pioglitazone versus diet and exercise on metabolic health and fat distribution in upper body obesityDiabetes Care20032631485214578253
   PubMed Web of Science ®Google Scholar
• SmithSRDe JongeLVolaufovaJEffect of pioglitazone on body composition and energy expenditure: a randomized controlled trialMetabolism200554243215562376
   PubMed Web of Science ®Google Scholar
• StamlerJVaccaroONeatonJDDiabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention TrialDiabetes Care199316434448432214
   PubMed Web of Science ®Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes UKPDS 35.: prospective observational studyBMJ20003214051210938048
   PubMed Web of Science ®Google Scholar
• TakagiTYamamuroATamitaKPioglitazone reduces neointimal tissue proliferation after coronary stent implantation in patients with type 2 diabetes mellitus: an intravascular ultrasound scanning studyAm Heart J2003146E512891212
   PubMed Web of Science ®Google Scholar
• TanMJohnsDGonzalez GalvezGEffects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trialClin Ther2004a266809315220012
   PubMed Web of Science ®Google Scholar
• TanMHJohnsDStrandJSustained effects of pioglitazone vs. glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetesDiabet Med2004b218596615270789
   PubMed Web of Science ®Google Scholar
• TiikkainenMHakkinenAMKorsheninnikovaEEffects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetesDiabetes20045321697615277403
   PubMed Web of Science ®Google Scholar
• TranMTNavarMDDavidsonMBComparison of the glycemic effects of rosiglitazone and pioglitazone in triple oral therapy in type 2 diabetesDiabetes Care2006291395616732030
   PubMed Web of Science ®Google Scholar
• UKPDSEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes UKPDS 34. UK Prospective Diabetes Study UKPDS. GroupLancet1998a352854659742977
   PubMed Web of Science ®Google Scholar
• UKPDSIntensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes UKPDS 33. UK Prospective Diabetes Study UKPDS. GroupLancet1998b352837539742976
   PubMed Web of Science ®Google Scholar
• WallaceTMLevyJCMatthewsDRAn increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized studyDiabet Med2004215687615154941
   PubMed Web of Science ®Google Scholar
• WilcoxRBousserMGBetteridgeDJEffects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive PROspective pioglitAzone Clinical Trial In macroVascular Events 04Stroke2007388657317290029
   PubMed Web of Science ®Google Scholar
• WillsonTMLambertMHKliewerSAPeroxisome proliferator-activated receptor gamma and metabolic diseaseAnnu Rev Biochem2001703416711395411
   PubMed Web of Science ®Google Scholar
• WinklerKKonradTFullertSPioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled studyDiabetes Care20032625889412941723
   PubMed Web of Science ®Google Scholar
• YamadaKJiJJYuanHProtective role of ATP-sensitive potassium channels in hypoxia-induced generalized seizureScience20012921543611375491
   PubMed Web of Science ®Google Scholar
• Yki-JarvinenHThe PROactive study: some answers, many questionsLancet20053661241216214581
   PubMed Web of Science ®Google Scholar
• ZhangFSjoholmKZhangQPioglitazone acutely influences glucose-sensitive insulin secretion in normal and diabetic human isletsBiochem Biophys Res Commun2006351750517084385
   PubMed Web of Science ®Google Scholar
• ZingmanLVHodgsonDMBastPHKir6.2 is required for adaptation to stressProc Natl Acad Sci U S A200299132788312271142
   PubMed Web of Science ®Google Scholar